ALX Oncology Holdings Inc.

NAS: ALXO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

ALX Oncology Holdings Inc.

After Hours

--Quotes are delayed by 20 min

Mar 24, 2023, 7:57 p.m.

ALXO

/zigman2/quotes/219511930/composite

4.67

Change

+0.01 +0.21%

Volume

Volume 5,783

Quotes are delayed by 20 min

/zigman2/quotes/219511930/composite

Previous close

$ 4.87

$ 4.66

Change

-0.21 -4.31%

Day low

Day high

$4.57

$4.93

52 week low

52 week high

$4.52

$19.85

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for ALX Oncology Holdings Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	2.07M	4.8M	1.18M	-	-
Sales Growth	-	132.03%	-75.35%	-	-
Cost of Goods Sold (COGS) incl. D&A	1.88M	4.36M	1.08M	736,000	1.47M
COGS excluding D&A	1.45M	3.93M	873,000	-	-
Depreciation & Amortization Expense	431,000	429,000	202,000	736,000	1.47M
Depreciation	431,000	429,000	202,000	736,000	1.47M
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	131.91%	-75.34%	-31.53%	99.18%
Gross Income	187,000	436,000	107,000	(736,000)	(1.47M)
Gross Income Growth	-	133.16%	-75.46%	-787.85%	-99.18%
Gross Profit Margin	-	-	-	-	-	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	13.87M	19.62M	43.77M	78.12M	125.97M
Research & Development	11.27M	16.31M	28.96M	55.47M	98.4M
Other SG&A	2.6M	3.31M	14.81M	22.65M	27.57M
SGA Growth	-	41.44%	123.10%	78.48%	61.25%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	1.15M	4.7M	-
EBIT after Unusual Expense	-	-	(44.81M)	(83.56M)	-
Non Operating Income/Expense	(2,000)	(5,000)	120,000	84,000	(260,000)
Non-Operating Interest Income	-	-	-	-	4.28M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	21,000	811,000	13,000	-
Interest Expense Growth	-	-	3,761.90%	-98.40%	-
Gross Interest Expense	-	21,000	811,000	13,000	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(13.69M)	(19.21M)	(45.5M)	(83.48M)	(123.42M)
Pretax Income Growth	-	-40.36%	-136.86%	-83.49%	-47.83%
Pretax Margin	-	-	-	-	-	NA
Income Tax	45,000	34,000	241,000	(21,000)	64,000
Income Tax - Current Domestic	1,000	1,000	241,000	(21,000)	64,000
Income Tax - Current Foreign	44,000	33,000	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(13.73M)	(19.24M)	(45.74M)	(83.46M)	(123.48M)
Minority Interest Expense	-	-	-	-	-
Net Income	(13.73M)	(19.24M)	(45.74M)	(83.46M)	(123.48M)
Net Income Growth	-	-40.14%	-137.70%	-82.47%	-47.95%
Net Margin Growth	-	-	-	-	-	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(13.73M)	(19.24M)	(45.74M)	(83.46M)	(123.48M)
Preferred Dividends	3.67M	4.03M	5.2M	-	-
Net Income Available to Common	(17.4M)	(23.27M)	(50.94M)	(83.46M)	(123.48M)
EPS (Basic)	(0.48)	(0.64)	(1.28)	(2.07)	(3.03)
EPS (Basic) Growth	-	-33.74%	-100.45%	-61.96%	-46.53%
Basic Shares Outstanding	36.49M	36.49M	39.84M	40.31M	40.7M
EPS (Diluted)	(0.48)	(0.64)	(1.28)	(2.07)	(3.03)
EPS (Diluted) Growth	-	-33.74%	-100.45%	-61.96%	-46.53%
Diluted Shares Outstanding	36.49M	36.49M	39.84M	40.31M	40.7M
EBITDA	(13.25M)	(18.75M)	(43.46M)	(78.12M)	(125.97M)
EBITDA Growth	-	-41.51%	-131.74%	-79.75%	-61.25%
EBITDA Margin	-	-	-	-	-	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

ALX Oncology Holdings Inc.

Annual Financials for ALX Oncology Holdings Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk